Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript

We don’t even know, they have to be on placebo but not knowing it clearly, we would tell them what the background of the molecule is being, an anti-depressant and so forth. And then of course, they say okay, the molecule works on serotonin and so forth. So then, they really speculate of course in their mind that, yes, maybe that’s why it is working better across different mood disorders that these patients may have, because we know ADHD does come with a lot of co-morbidity, with things like anxiety, depression, bipolar or other mood disorders. And clearly, it looks like again, anecdotally that probably it was happening across different areas, not just ADHD.

Jack Padovano: Great. Very helpful. Thank you.

Operator: Thank you. This concludes our question and answer session. I would now like to turn it back over to Jack for closing remarks.

Jack Khattar: Thank you. In concluding our call this afternoon, we remain focused on first driving the long-term growth of the company by continuing to drive significant growth with Qelbree and together with the recovery and the rest of the portfolio generates strong cash flows, allowing us to continue our investments in our pipeline. And second progressing our innovative R&D portfolio differentiated first-in-class molecules that have several exciting and upcoming clinical milestones and catalysts. Thanks for joining us this afternoon, we look forward to updating you on our next call.

Operator: Thank you everybody for your participation in today’s conference call. This does conclude the program. You may now disconnect.